Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

NCT03784326 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03784326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03784326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 19, 2019
Completion date
December 31, 2026
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage ii esophageal adenocarcinoma ajcc v8, clinical stage ii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iia esophageal adenocarcinoma ajcc v8, clinical stage iia gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iib esophageal adenocarcinoma ajcc v8, clinical stage iib gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iii esophageal adenocarcinoma ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ib esophageal adenocarcinoma ajcc v8, pathologic stage ib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ic esophageal adenocarcinoma ajcc v8, pathologic stage ic gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ii esophageal adenocarcinoma ajcc v8, pathologic stage ii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iia esophageal adenocarcinoma ajcc v8, pathologic stage iia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iib esophageal adenocarcinoma ajcc v8, pathologic stage iib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iii esophageal adenocarcinoma ajcc v8, pathologic stage iii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiia esophageal adenocarcinoma ajcc v8, pathologic stage iiia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiib esophageal adenocarcinoma ajcc v8, pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8